1. Home
  2. BHAT vs GLTO Comparison

BHAT vs GLTO Comparison

Compare BHAT & GLTO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

BHAT

Blue Hat Interactive Entertainment Technology

HOLD

Current Price

$1.26

Market Cap

59.1M

ML Signal

HOLD

Logo Galecto Inc.

GLTO

Galecto Inc.

HOLD

Current Price

$34.99

Market Cap

23.7M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
BHAT
GLTO
Founded
2010
2011
Country
China
Denmark
Employees
N/A
N/A
Industry
Recreational Games/Products/Toys
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
59.1M
23.7M
IPO Year
2019
2020

Fundamental Metrics

Financial Performance
Metric
BHAT
GLTO
Price
$1.26
$34.99
Analyst Decision
Strong Buy
Analyst Count
0
1
Target Price
N/A
$36.00
AVG Volume (30 Days)
79.5K
113.4K
Earning Date
11-26-2025
11-06-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$18,972,415.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$1.07
$2.01
52 Week High
$24.50
$33.60

Technical Indicators

Market Signals
Indicator
BHAT
GLTO
Relative Strength Index (RSI) 41.97 71.35
Support Level $1.25 $24.53
Resistance Level $1.39 $30.03
Average True Range (ATR) 0.11 3.85
MACD 0.00 0.01
Stochastic Oscillator 19.51 74.16

Price Performance

Historical Comparison
BHAT
GLTO

About BHAT Blue Hat Interactive Entertainment Technology

Blue Hat Interactive Entertainment Technology is focused on commodity trading, including chemicals, jewelry, and precious metals such as gold. It operates a gold and diamond trading and supply chain business. Its business model encompasses physical gold trading, diamond trading, gold derivatives trading, and the development of AI-enabled trading platforms. Its segments include Diamond trading, Commodity trading, Information service, Interactive toys - animation series, and Interactive toys - game series. It derives revenue from Diamond trading. The majority of its revenues are generated in PRC.

About GLTO Galecto Inc.

Galecto Inc is a clinical-stage biotechnology company developing therapeutics designed to target the biological processes that lie at the heart of cancer and liver diseases. Its initial focus is on the development of small-molecule inhibitors of galectin-3 and lysyl oxidase-like 2, or LOXL2. Its product candidate GB0139 is for the treatment of severe fibrotic lung diseases such as idiopathic pulmonary fibrosis, or IPF, a life-threatening progressive fibrotic disease of the lung. Its product GB1211, a selective oral galectin-3 inhibitor for the treatment of fibrosis related to non-alcoholic steatohepatitis, or NASH, and GB2064, a selective oral inhibitor of LOXL2 that it initially plans to develop for the treatment of myelofibrosis.

Share on Social Networks: